Activity Information

The Rheumatology Review Course 2024 features key updates covering a wide range of rheumatology diseases. This activity contains eight individual video lectures approximately 45 minutes in length, including a Q&A session, and is ideal for anyone needing an introduction to the latest research in rheumatology or simply seeking an activity available at your convenience.

The Review Course is a popular session that takes place annually during ACR Convergence, the ACR’s annual meeting. Talks include:

• To Be or Not to Behcet’s? Differentials for Oral Ulcers
• Psoriatic Arthritis Management Review
• Geriatric Concerns in Rheumatology
• Updates in Sarcoidosis
• Pain Management for the Rheumatologist
• Beyond the Surface: Management of Calcinosis in Connective Tissue Diseases
• Case-Based Approach to Metabolic Bone Disease
• Challenging Cases in Rheumatoid Arthritis
  

Registration is discounted for ACR/ARP members. If you are not a member, consider joining the ACR/ARP.

ACR/ARP Member: $399
ACR/ARP Potential Member: $599

For this activity, each learner must:

• Complete a pre-test 
• Complete a post-test and have a passing score of 70% or higher 
• Complete the activity evaluation 

Target Audience

Rheumatologists, physicians, primary care providers, fellows in training, advanced practice nurses, nurses, occupational therapists, physical therapists, pharmacists, residents, and healthcare providers who care for patients with rheumatic diseases; professionals interested in or engaged in rheumatology research.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

• Apply the concept of complex aphthosis.
• Identify active disease in each PsA domain.
• Describe the unique aspects and considerations when caring for older adults with rheumatic diseases.
• Recognize areas of practice vulnerability to disparity, racism, and bias.
• Identify what calcinosis is in connective tissue diseases.
• Identify presentation, work-up, and treatment for hypophosphatasia. 
• Discuss recent data informing therapeutic options available in an MTX-IR patient.
• Implement strategies to address multi-morbidity in management of RA and D2T RA.

CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.

Designation Statement

The American College of Rheumatology designates this Enduring Material for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants can claim up to 0.25 AMA PRA Category 1 Credit(s)™ for completing the pre-and post-assessments, and up to 6.75 AMA PRA Category 1 Credit(s)™ for attending the Rheumatology Review Course 2024.

CME credit must be claimed by December 18, 2027, at 11:59 PM ET.

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal. 

MOC points must be claimed by December 18, 2027, at 11:59 PM ET.

Financial Relationships Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership interest
9. Royalties and/or patent beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

*All of the relevant financial relationships listed for these individuals have been mitigated.

Planning/Faculty Team Members

The following Content Bundle Planning/Faculty Team Members have the following financial relationships with ineligible companies to disclose.

• Johannes Nowatzky, MD - Soligenix: Advisor or Review Panel Member (Ongoing)

• Ana-Maria Orbai, MD, MHS - AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing) 

• Namrata Singh, MD,MSc – Mustang Bio; Consultant

• Julie Paik, MD, MHS - Alexion: Grant/Research Support (Ongoing); ArgenX: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Guidepoint: Consultant (Ongoing); Priovant: Grant/Research Support (Ongoing)

• Lesley Ann Saketkoo, MD, MPH - Kyverna: Grant/Research Support (Ongoing); Mallinckrodt: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing)

• Daniel Clauw, MD - Tonix: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Pfizer, Lilly; Lundbeck; Virios; Swing; Neurometrix; Consultant (Ongoing)

• Antonia Valenzuela, MD, MS – Board Member: SCTC (Secretary), Grant/Research Support: SCTC/PANLAR

• Laura Carbone, MD, MS – Grant funded research; NIH/NIA, R01AG079118, Calculator for Length of Use of Bisphosphonates (CLUB); Department of Defense (DOD), SCI200001, Development of Novel Soluble Epoxide Hydrolase Inhibitotor as a Strategy for Treating Neuropathic Pain in Patients with Spinal Cord Injury; Off-label medication with supporting evidence will be discussed.

• Iain McInnes, PhD, FRCP - AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)

Review Team Members

The following team members have no relevant financial relationship(s) with ineligible companies to disclose.

• Adena Batterman, LCSW, MSW
• Rebecca Manno, MD, MPH
• Carlos Ferreira, MA

Planning Team Members

The following planning team members have no relevant financial relationship(s) with ineligible companies to disclose.

• Kai Sun, MD, MS, RhMSUS
• Myria Stanley, MS, DES
• Sharon Ross
• Priyanjali Pulipati, MBBS
• Noelle Rolle, MBBS, FACP, FACR
  

*All of the relevant financial relationships listed for all individuals involved in the activity have been mitigated.

Corporate Support OR Acknowledgement of Support

No commercial support was provided for this activity.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.